About Uncharacterized protein C1orf159
Uncharacterized protein C1orf159 (C1orf159) is a protein
from Homo sapiens identified by UniProt accession
Q96HA4, 380 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Uncharacterized protein C1orf159 |
| UniProt accession | Q96HA4 |
| Gene | C1orf159 |
| Organism | Homo sapiens |
| Length | 380 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.31
- blood phosphate measurement · score 0.25
- calcium measurement · score 0.10
- blood protein measurement · score 0.04
- combined immunodeficiency with skin granulomas · score 0.04
- neutropenia, severe congenital, 2, autosomal dominant · score 0.04
- urate measurement · score 0.04
- body height · score 0.04
- severe combined immunodeficiency due to IKK2 deficiency · score 0.03
- X-Linked Combined Immunodeficiency Diseases · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96HA4-F1 | alphafold | PREDICTED | 49.18 | — |
Amino-acid sequence (380 residues)
MALRHLALLA GLLVGVASKS MENTVTRNST AVINTQAEGT LSPPGLSSLP VVREWALTHT AQLPECCVDV VGVNASCPGA SLCGPGCYRR WNADGSASCV RCGNGTLPAY NGSECRSFAG PGAPFPMNRS SGTPGRPHPG APRVAASLFL GTFFISSGLI LSVAGFFYLK RSSKLPRACY RRNKAPALQP GEAAAMIPPP QSSGNSSCRI PLWGFPSLGQ SQGALWVCPQ TGLPGSGSRP PLPGSPGDPP TRQGQGRIWL VPPALDLSWI WPAPPARPPL IPVTSMLFPV PETWGLQERR THHDRADPQY LLLLEVQLHP RTDAAGLRQA LLSSHRFSGA GSGGPKSQPV RKPRYVRRER PLDRATDPAA FPGEARISNV
Explore Uncharacterized protein C1orf159 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets